There's mention of PEB in the HY financial report from CDY released yesterday:
The Consolidated Entity licenced its cancer diagnostic patents to Pacific Edge Biotechnology Limited (“Pacific Edge”) in 2010 for the use in their bladder cancer diagnostic test. The test was launched in Australia and New Zealand in 2012 and Pacific Edge reported on the opening of their USA based laboratory in September 2012. Cxbladder® was launched in the USA in March 2013 after Pacific Edge received their CLIA certification for its laboratories. In August 2013 the Consolidated Entity received a milestone payment in Pacific Edge shares (1,084,622 shares) at the time their sales activities commenced in the United States. The Pacific Edge shares have subsequently been sold on market.
During the half year ended 31 December 2014 Pacific Edge paid to the Consolidated Entity $18,040 in royalties in relation to their license and announced the launch of a new triaging product for bladder cancer.
Pretty sure we already knew that CDY needed the cash sold their shares, but does this amount of royalties paid by PEB give any insight on sales?